Caribou Biosciences Announces Dosing Of First Patient In The Cammouflage Phase 1 Trial Of CB-011, An Allogeneic Anti-BCMA CAR-T Cell Therapy For The Treatment Of Relapsed Or Refractory Multiple Myeloma

Press/Media

Period29 Mar 2023

Media coverage

1

Media coverage